Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
Claus BachertAsif H KhanStella E LeeClaire HopkinsAnju T PetersWytske FokkensAmy PraestgaardAmr RadwanScott NashJuby A Jacob-NaraYamo DenizPaul J RowePublished in: International forum of allergy & rhinology (2023)
Most patients with CRSwNP in the SINUS study had type 2 inflammation. Dupilumab demonstrated robust efficacy across definitions of type 2 inflammation, consistent with its profile as an inhibitor of IL-4 and IL-13 signaling, key and central drivers of type 2 inflammation in CRSwNP. This article is protected by copyright. All rights reserved.